We'll just have to wait and see. I expect any deal, if we are successful in the phase 2, will have a six or seven figures upfront payment with most of it back loaded in royalties and sales milestones.
I don't think BP is going to pay up for a drug that may not have much of a use in a couple years. Again, BP pays up for certainty not risky moonshots. They are bankers not venture capitalists.
History has shown that is what we are capable of negotiating (B-UP) and also that we have a history of pursuing hot indications that end up being economically unfeasible to continue with (B-ABSSSI and B-OM). If Leo can 't find a suitable partnership for those that he is happy with, why do you think B-COVID will be different?
We couldn't find a partner on either of those for 1/3 the value of what Leo wanted? Because we sold 2/3 of the company through dilution since the end of B-OM to keep ourselves afloat. And that dilution affects every indication in the future, not just B-ABSSSI or B-OM.
Go IPIX!
News 
Market Data 
Discover 
